Prader-Willi Syndrome Documentary

Prader-Willi Syndrome, FDA and Soleno

Soleno Therapeutics Stock Rockets 34% Pre-Market After FDA Approves Prader-Willi Syndrome Drug: Retail Sentiment Peaks

Shares of Soleno Therapeutics (SLNO) rocketed nearly 34% in premarket trading on Thursday after the biopharmaceutical company received approval from the Food and Drug Administration (FDA) for its VYKAT XR extended-release tablets.

MarketWatch · 2d

Soleno Shares Soar Premarket on FDA Approval of Vykat XR

Soleno on Wednesday said the FDA approved its Vykat XR extended-release tablets for the treatment of hyperphagia, a chronic and life-threatening feeling of intense, persistent hunger, in people ages 4 and older with Prader-Willi syndrome.

Business Insider · 2d

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

First approved therapy to address hyperphagia in individuals with Prader-Willi syndromeManagement to host conference call and webcast today,

Investing2d

FDA approves new Prader-Willi syndrome treatment

Stacy Ward, CEO of the Prader-Willi Syndrome Association | USA, and Susan Hedstrom, Executive Director of the Foundation for Prader-Willi Research, also acknowledged the approval as a pivotal ...

Nature7y

Imprinting and Genetic Disease: Angelman, Prader-Willi and Beckwith-Weidemann Syndromes

Angelman syndrome (Figure 1 ... the same region on chromosome 15 has been implicated for both Angelman and Prader-Willi syndromes. However, it is the loss of the maternal contribution that ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Prader-Willi Syndrome, FDA and Soleno

Trending now